Antidiabetic Properties of Rose Hip
Not Applicable
Completed
- Conditions
- Obesity
- Interventions
- Dietary Supplement: Rose hip
- Registration Number
- NCT01316016
- Lead Sponsor
- Lund University
- Brief Summary
The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- BMI > 30
- willingness to participate in the study
- willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study
Exclusion Criteria
- diabetes
- previous or ongoing insulin treatment
- abnormal thyroid status
- abnormal liver status
- abnormal kidney status
- known gastrointestinal disorder
- pregnancy
- suspected allergy to ingredients of the drinks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Rose hip Rose hip -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does rose hip powder modulate in obese individuals to reduce type 2 diabetes risk markers in the NCT01316016 trial?
How does rose hip supplementation compare to metformin in improving HbA1c and lipid profiles in obese patients with prediabetes?
Which biomarkers (e.g., adiponectin, inflammatory cytokines) predict response to rose hip powder in the NCT01316016 trial for type 2 diabetes risk reduction?
What are the known or potential adverse events of rose hip powder in obese populations, and how do they compare to antidiabetic drug side effects?
Are there synergistic effects of combining rose hip powder with GLP-1 receptor agonists or SGLT2 inhibitors in managing obesity-related diabetes risk?
Trial Locations
- Locations (1)
Endocrinology Clinic, Lund University Hospital
🇸🇪Lund, Sweden